Stock BIO BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Biotest AG Xetra

Equities

BIO

DE0005227201

Market Closed - Xetra
Other stock markets
 16:12:06 28/06/2024 BST 		5-day change 1st Jan Change
42.2 EUR +2.93% Intraday chart for Biotest AG +2.93% -0.94%
06-17 Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies CI
05-07 Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Biotest : Rules of Procedure of the Supervisory Board PDF, 184 KB
PU
Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'
EQ
Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo
EQ
Biotest : Speech of Peter Janssen - German Version
PU
Biotest AG: Annual General Meeting approves dividend distribution
EQ
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
EQ
Biotest AG opens 12th plasma collection centre in Germany
EQ
Biotest AG increased sales by 32% in the financial year 2023
EQ
Biotest : Sustainability report Declaration of compliance 2023
PU
Biotest : Invitation / Agenda of Annual General Meeting 2024
PU
Biotest : Notes on agenda item 1 - German Version
PU
Biotest achieves EBIT forecast for 2023
EQ
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
EQ
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
Biotest AG opens 11th plasma collection centre in Germany
EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)
EQ
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIO3 Stock
  4. BIO Stock
  5. News Biotest AG
  6. Press Releases